140 related articles for article (PubMed ID: 34261618)
1. PNPLA3 is the dominant SNP linked to liver disease severity at time of first referral to a tertiary center.
Balcar L; Semmler G; Oberkofler H; Zandanell S; Strasser M; Datz L; Niederseer D; Feldman A; Stickel F; Datz C; Paulweber B; Aigner E
Dig Liver Dis; 2022 Jan; 54(1):84-90. PubMed ID: 34261618
[TBL] [Abstract][Full Text] [Related]
2. Relevance of
Elmansoury N; Megahed AA; Kamal A; El-Nikhely N; Labane M; Abdelmageed M; Daly AK; Wahid A
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674389
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
[TBL] [Abstract][Full Text] [Related]
4. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
[TBL] [Abstract][Full Text] [Related]
5. PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center.
Semmler G; Balcar L; Oberkofler H; Zandanell S; Strasser M; Niederseer D; Feldman A; Stickel F; Strnad P; Datz C; Paulweber B; Aigner E
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33804385
[TBL] [Abstract][Full Text] [Related]
6. PNPLA3 risk allele is associated with risk of hepatocellular carcinoma but not decompensation in compensated cirrhosis.
Urias E; Tedesco NR; Burkholder DA; Moran IJ; Miller MJ; Jasty VSJ; Patil S; Zoellner S; Wijarnpreecha K; Chen VL
Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38780253
[TBL] [Abstract][Full Text] [Related]
7. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children.
Lee KJ; Moon JS; Kim NY; Ko JS
Pediatr Obes; 2022 Feb; 17(2):e12852. PubMed ID: 34490745
[TBL] [Abstract][Full Text] [Related]
8. African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population.
Cavalcante LN; Porto J; Mazo D; Longatto-Filho A; Stefano JT; Lyra AC; Carrilho FJ; Reis RM; Alves VAF; Sanyal AJ; Oliveira CP
Ann Hepatol; 2022; 27(6):100728. PubMed ID: 35710086
[TBL] [Abstract][Full Text] [Related]
9. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N
Clin Transl Gastroenterol; 2021 Sep; 12(9):e00400. PubMed ID: 34506332
[TBL] [Abstract][Full Text] [Related]
10. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
[TBL] [Abstract][Full Text] [Related]
11. Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis.
Beaudoin JJ; Liang T; Tang Q; Banini BA; Shah VH; Sanyal AJ; Chalasani NP; Gawrieh S
Alcohol Clin Exp Res; 2021 Apr; 45(4):709-719. PubMed ID: 33616244
[TBL] [Abstract][Full Text] [Related]
12. PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: a genetic association study.
Rauff B; Alzahrani B; Chudhary SA; Nasir B; Mahmood S; Bhinder MA; Faheem M; Amar A
BMC Gastroenterol; 2022 Aug; 22(1):401. PubMed ID: 36028802
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Genetic Polymorphism in Response to Body Weight Reduction in Japanese Patients with Nonalcoholic Fatty Liver Disease.
Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Itoh Y
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33922278
[TBL] [Abstract][Full Text] [Related]
14. No association of NAFLD-related polymorphisms in PNPLA3 and TM6SF2 with all-cause and cardiovascular mortality in an Austrian population study.
Semmler G; Balcar L; Wernly S; Datz L; Semmler M; Rosenstatter L; Stickel F; Aigner E; Wernly B; Datz C
Wien Klin Wochenschr; 2024 May; 136(9-10):251-257. PubMed ID: 37103556
[TBL] [Abstract][Full Text] [Related]
15. Genetic Susceptibility to Chronic Liver Disease in Individuals from Pakistan.
Raja AM; Ciociola E; Ahmad IN; Dar FS; Naqvi SMS; Moaeen-Ud-Din M; Kaukab Raja G; Romeo S; Mancina RM
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443539
[TBL] [Abstract][Full Text] [Related]
16. SERPINA1 and HSD17B13 Gene Variants in Patients with Liver Fibrosis and Cirrhosis.
Basyte-Bacevice V; Skieceviciene J; Valantiene I; Sumskiene J; Petrenkiene V; Kondrackiene J; Petrauskas D; Lammert F; Kupcinskas J
J Gastrointestin Liver Dis; 2019 Sep; 28(3):297-302. PubMed ID: 31517326
[TBL] [Abstract][Full Text] [Related]
17. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
[TBL] [Abstract][Full Text] [Related]
18. The Risk of Cirrhosis and Its Complications Based on PNPLA3 rs738409 G Allele Frequency.
Shao X; Uojima H; Arai T; Ogawa Y; Setsu T; Atsukawa M; Furuichi Y; Arase Y; Horio K; Hidaka H; Nakazawa T; Kako M; Kagawa T; Iwakiri K; Nakajima A; Terai S; Tanaka Y; Koizumi W
Dig Dis; 2022; 40(5):625-634. PubMed ID: 34808618
[TBL] [Abstract][Full Text] [Related]
19. Frequency of the PNPLA3 rs738409 polymorphism and other genetic loci for liver disease in a Guatemalan adult population.
Lazo M; Xie J; Alvarez CS; Parisi D; Yang S; Rivera-Andrade A; Kroker-Lobos MF; Groopman JD; Guallar E; Ramirez-Zea M; Arking DE; McGlynn KA
Liver Int; 2022 Jun; 42(6):1470-1474. PubMed ID: 35365950
[No Abstract] [Full Text] [Related]
20. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.
Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Gustot T; Deviere J; Debette S; Amouyel P; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
Int J Cancer; 2019 Feb; 144(3):533-544. PubMed ID: 30289982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
